JP2005521643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005521643A5 JP2005521643A5 JP2003545797A JP2003545797A JP2005521643A5 JP 2005521643 A5 JP2005521643 A5 JP 2005521643A5 JP 2003545797 A JP2003545797 A JP 2003545797A JP 2003545797 A JP2003545797 A JP 2003545797A JP 2005521643 A5 JP2005521643 A5 JP 2005521643A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- angptl3
- antibody
- medicament
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 18
- 101100001705 Mus musculus Angptl3 gene Proteins 0.000 claims 7
- 230000002757 inflammatory effect Effects 0.000 claims 6
- 208000019423 liver disease Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 102000006495 integrins Human genes 0.000 claims 3
- 108010044426 integrins Proteins 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 206010019773 Hepatitis G Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000010595 endothelial cell migration Effects 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33242901P | 2001-11-16 | 2001-11-16 | |
| US60/332,429 | 2001-11-16 | ||
| PCT/US2002/036865 WO2003044172A2 (en) | 2001-11-16 | 2002-11-13 | Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009259497A Division JP2010100624A (ja) | 2001-11-16 | 2009-11-13 | アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005521643A JP2005521643A (ja) | 2005-07-21 |
| JP2005521643A5 true JP2005521643A5 (enExample) | 2006-04-06 |
| JP5105696B2 JP5105696B2 (ja) | 2012-12-26 |
Family
ID=23298191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003545797A Expired - Fee Related JP5105696B2 (ja) | 2001-11-16 | 2002-11-13 | アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 |
| JP2009259497A Pending JP2010100624A (ja) | 2001-11-16 | 2009-11-13 | アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009259497A Pending JP2010100624A (ja) | 2001-11-16 | 2009-11-13 | アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7267819B2 (enExample) |
| EP (1) | EP1451578B1 (enExample) |
| JP (2) | JP5105696B2 (enExample) |
| KR (2) | KR101012904B1 (enExample) |
| CN (2) | CN1615440A (enExample) |
| AU (1) | AU2002348286B2 (enExample) |
| CA (1) | CA2464542C (enExample) |
| ES (1) | ES2429034T3 (enExample) |
| IL (2) | IL161542A0 (enExample) |
| MX (1) | MXPA04004609A (enExample) |
| NO (1) | NO336021B1 (enExample) |
| NZ (1) | NZ532852A (enExample) |
| WO (1) | WO2003044172A2 (enExample) |
| ZA (1) | ZA200403070B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| ES2429034T3 (es) | 2001-11-16 | 2013-11-12 | Genentech, Inc. | Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas |
| JP5349752B2 (ja) * | 2003-08-21 | 2013-11-20 | デュシェネ インク | 微量栄養素サプリメント |
| AU2005269716B2 (en) * | 2004-07-20 | 2011-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| MX2007000783A (es) | 2004-07-20 | 2007-04-09 | Genentech Inc | Inhibidores de proteina angiopoietina tipo 4, combinaciones y su uso. |
| US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| US7807645B2 (en) | 2005-09-23 | 2010-10-05 | The Regents Of The University Of California | Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment |
| CA2672049C (en) | 2006-12-08 | 2016-05-10 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| US8354111B2 (en) | 2008-04-14 | 2013-01-15 | Hadasit Medical Research Services And Development Ltd. | Stable cell binding chimeric peptides |
| CN101852805B (zh) * | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| PE20160507A1 (es) * | 2009-07-14 | 2016-05-20 | Scripps Research Inst | Diferenciacion de celulas madre mesenquimales |
| AU2015200969A1 (en) * | 2010-01-08 | 2015-03-19 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| CN106146591B (zh) | 2010-01-08 | 2020-07-31 | Ionis制药公司 | 血管生成素样3表达的调节 |
| JP5838474B2 (ja) * | 2010-02-02 | 2016-01-06 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | ポリマーの配列を決定するための制御されたトンネルギャップデバイス |
| US20130330752A1 (en) * | 2011-01-29 | 2013-12-12 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CA2862485C (en) * | 2012-01-24 | 2021-05-11 | Inter-K Pty Limited | Peptide agents for cancer therapy |
| UY35368A (es) * | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
| CN104062432B (zh) * | 2013-03-22 | 2016-01-20 | 中山大学 | ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用 |
| KR102482890B1 (ko) | 2013-05-01 | 2022-12-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법 |
| MX383753B (es) | 2013-12-24 | 2025-03-14 | Ionis Pharmaceuticals Inc | Modulación de la expresión similar a la angiopoyetina tipo 3. |
| SI3137605T1 (sl) | 2014-05-01 | 2021-02-26 | Ionis Pharmaceuticals, Inc. | Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega |
| CN105021827B (zh) * | 2015-07-17 | 2016-09-28 | 北京大学第一医院 | 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用 |
| CA2999341A1 (en) | 2015-11-06 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Modulating apolipoprotein (a) expression |
| US10582702B2 (en) * | 2016-02-04 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered ANGPTL8 gene |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| KR102737464B1 (ko) | 2017-09-14 | 2024-12-02 | 애로우헤드 파마슈티컬스 인코포레이티드 | 안지오포이에틴-유사 3 (ANGPTL3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물, 및 사용 방법 |
| AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
| WO2020099482A2 (en) * | 2018-11-13 | 2020-05-22 | Lipigon Pharmaceuticals Ab | Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| WO2021001804A1 (en) * | 2019-07-04 | 2021-01-07 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
| CN111122872B (zh) * | 2019-11-20 | 2023-01-20 | 中山大学附属第一医院 | 血管生成素样蛋白7在心力衰竭预后评估中的应用 |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
| CN114934021B (zh) * | 2022-04-21 | 2023-08-08 | 复旦大学附属儿科医院 | 一种Angptl3敲除的鼠永生化足细胞系及其应用 |
| CN120254294B (zh) * | 2025-06-05 | 2025-09-09 | 南昌大学第一附属医院 | Angptl3在乙肝相关慢加急性肝衰竭预后中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596850B1 (en) * | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
| EP0917878A4 (en) | 1997-02-26 | 2004-05-19 | Toray Industries | REMEDIES FOR HEPATITIS |
| WO1999058660A1 (en) * | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
| US5972338A (en) * | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
| US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| AU3661199A (en) * | 1998-04-27 | 1999-11-16 | Zymogenetics Inc. | Novel polypeptide growth factors and materials and methods for making them |
| AU4643699A (en) * | 1998-06-24 | 2000-01-10 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
| AU768694B2 (en) * | 1999-03-08 | 2004-01-08 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| ES2429034T3 (es) | 2001-11-16 | 2013-11-12 | Genentech, Inc. | Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas |
-
2002
- 2002-11-13 ES ES02782310T patent/ES2429034T3/es not_active Expired - Lifetime
- 2002-11-13 JP JP2003545797A patent/JP5105696B2/ja not_active Expired - Fee Related
- 2002-11-13 CN CNA028271920A patent/CN1615440A/zh active Pending
- 2002-11-13 KR KR1020047007410A patent/KR101012904B1/ko not_active Expired - Fee Related
- 2002-11-13 MX MXPA04004609A patent/MXPA04004609A/es active IP Right Grant
- 2002-11-13 EP EP02782310.3A patent/EP1451578B1/en not_active Expired - Lifetime
- 2002-11-13 NZ NZ532852A patent/NZ532852A/en not_active IP Right Cessation
- 2002-11-13 KR KR1020107004734A patent/KR20100029861A/ko not_active Ceased
- 2002-11-13 AU AU2002348286A patent/AU2002348286B2/en not_active Ceased
- 2002-11-13 IL IL16154202A patent/IL161542A0/xx not_active IP Right Cessation
- 2002-11-13 CN CN2010102426068A patent/CN101905024A/zh active Pending
- 2002-11-13 CA CA2464542A patent/CA2464542C/en not_active Expired - Fee Related
- 2002-11-13 WO PCT/US2002/036865 patent/WO2003044172A2/en not_active Ceased
- 2002-11-15 US US10/298,461 patent/US7267819B2/en not_active Expired - Lifetime
-
2004
- 2004-04-22 ZA ZA2004/03070A patent/ZA200403070B/en unknown
- 2004-06-09 NO NO20042410A patent/NO336021B1/no not_active IP Right Cessation
-
2006
- 2006-09-29 US US11/537,567 patent/US20070134250A1/en not_active Abandoned
-
2008
- 2008-05-28 US US12/128,545 patent/US8541376B2/en not_active Expired - Fee Related
-
2009
- 2009-11-13 JP JP2009259497A patent/JP2010100624A/ja active Pending
-
2010
- 2010-02-11 IL IL203894A patent/IL203894A/en not_active IP Right Cessation